Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-19T13:24:25.569Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuropsychiatric complications in a patient with Marfan syndrome

Published online by Cambridge University Press:  27 February 2013

Chin-Pang Lee ,
Chun-Lin Chu ,
Chia-Yih Liu  and
Chia-Hsiang Chen
Chin-Pang Lee
Affiliation:
Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Chun-Lin Chu
Affiliation:
Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, Chang Gung University, Taoyuan, Taiwan
Chia-Yih Liu
Affiliation:
Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, Chang Gung University, Taoyuan, Taiwan
Chia-Hsiang Chen*
Affiliation:
Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, Chang Gung University, Taoyuan, Taiwan Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan Institue of Medical Science, Tzu Chi University, Hualien, Taiwan
*
Dr. Chia-Hsiang Chen, Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences, National Health Research Institutes, Zhunan 350, Taiwan. Tel: +886-37-246166 ext. 36713; Fax: +886-37-586453; E-mail: cchen@nhri.org.tw
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Marfan syndrome (MFS) is an autosomal dominant disorder of fibrillin-1 gene mutations, with the involvement of cardiovascular, skeletal, and ocular systems. In addition to physical abnormalities, MFS patients are also found to be susceptible to schizophrenia and other psychiatric conditions.

Objectives

Awareness of the association between MFS and psychiatric conditions would improve the clinical management of MFS patients to reduce the risk or even to prevent the development of psychiatric complications in MFS patients.

Methods

Here, we describe a male MFS patient who manifested incoherent speech and impaired cognitive and social function at the age of 40 years.

Results and conclusion

His mental dysfunction could be attributed to his bilateral cerebral infarction, which is a neurovascular complication associated with MFS.

Keywords

Marfan syndromeneurovascular complicationorganic brain syndromestroke
Type
Case Report
Information
Acta Neuropsychiatrica , Volume 25 , Issue 4 , August 2013 , pp. 245 - 247
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Caadas, V, Vilacosta, I, Bruna, I, Fuster, V. Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol 2010;7:256–265.CrossRefGoogle Scholar
2.Van Den Bossche, MJA, Van Wallendael, KLP, Strazisar, M, Sabbe, B, Del-Favero, J. Co-occurrence of Marfan syndrome and schizophrenia: what can be learned? Eur J Med Genet 2012;55:252–255.CrossRefGoogle ScholarPubMed
3.Lemberg, M, Thompson, AW. Marfan syndrome and schizophrenia: a case report and literature review. Gen Hosp Psychiatry 2010;32:228.e9–228.e10.CrossRefGoogle ScholarPubMed
4.Rao, NP, Loganathan, S, Prakash, O, Varghese, M. Use of electroconvulsive therapy for schizophrenia with comorbid Marfan syndrome. J ECT 2009;25:276–277.CrossRefGoogle ScholarPubMed
5.Mercuro, G, Carpiniello, B, Ruscazio, Met al. Association between psychiatric disorders and Marfan's syndrome in a large Sardinian family with a high prevalence of cardiac abnormalities. Clin Cardiol 1997;20:243–245.CrossRefGoogle Scholar
6.Wanson, L, Godfroid, IO. Psychiatric symptoms and Marfan: part of the syndrome or incidental to it? World J Biol Psychiatry 2002;3:229–230.CrossRefGoogle ScholarPubMed
7.Hofman, KJ, Bernhardt, BA, Pyeritz, RE. Marfan syndrome: neuropsychological aspects. Am J Med Genet 1988;31:331–338.CrossRefGoogle ScholarPubMed
8.Peters, KF, Kong, F, Horne, R, Francomano, CA, Biesecker, BB. Living with Marfan syndrome I. Perceptions of the condition. Clin Genet 2001;60:273–282.CrossRefGoogle ScholarPubMed
9.Kalsi, G, Mankoo, BS, Brynjolfsson, Jet al. The Marfan syndrome gene locus as a favoured locus for susceptibility to schizophrenia. Psychiatr Genet 1994;4:219–227.CrossRefGoogle ScholarPubMed
10.Schievink, WI, Michels, VV, Piepgras, DG. Neurovascular manifestations of heritable connective tissue disorders. A review. Stroke 1994;25:889–903.CrossRefGoogle ScholarPubMed
11.Kingwell, B, Boutouyrie, P. Genetic influences on the arterial wall. Clin Exp Pharmacol Physiol 2007;34:652–657.CrossRefGoogle ScholarPubMed
12.Wityk, RJ, Zanferrari, C, Oppenheimer, S. Neurovascular complications of Marfan syndrome: a retrospective, hospital-based study. Stroke 2002;33:680–684.CrossRefGoogle ScholarPubMed
13.Lawler, CP, Prioleau, C, Lewis, MMet al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612–627.CrossRefGoogle ScholarPubMed
14.Burris, KD, Molski, TF, Xu, Cet al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381–389.CrossRefGoogle ScholarPubMed
15.Shapiro, DA, Renock, S, Arrington, Eet al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400–1411.CrossRefGoogle ScholarPubMed
16.Zhang, JY, Kowal, DM, Nawoschik, SP, Lou, Z, Dunlop, J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006;71:521–529.CrossRefGoogle ScholarPubMed
17.Potkin, SG, Saha, AR, Kujawa, MJet al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–690.CrossRefGoogle ScholarPubMed
18.Katzman, MA. Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. J Affect Disord 2011;128(Suppl. 1):S11–S20.CrossRefGoogle ScholarPubMed
19.Elliott, MSJ, Ballard, CG, Kalaria, RN, Perry, R, Hortobgyi, T, Francis, PT. Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain 2009;132(Pt 7):1858–1865.CrossRefGoogle ScholarPubMed
20.Salazar-Colocho, P, Del Ro, J, Frechilla, D. Neuroprotective effects of serotonin 5-HT 1A receptor activation against ischemic cell damage in gerbil hippocampus: involvement of NMDA receptor NR1 subunit and BDNF. Brain Res 2008;1199:159–166.CrossRefGoogle ScholarPubMed
21.Leopoldo, M, Lacivita, E, Berardi, F, Perrone, R, Hedlund, PB. Serotonin 5-HT7 receptor agents: structure–activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 2011;129:120–148.CrossRefGoogle ScholarPubMed
22.Hedlund, PB, Sutcliffe, JG. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive–compulsive disorder. Neurosci Lett 2007;414:247–251.CrossRefGoogle Scholar